RPG Lifesciences Q2 highlights -
Sales - 154 vs 135 cr, up 14 pc
EBITDA - 39 vs 31 cr , up 26 pc (margins at 24 vs 22 pc)
PAT - 26 vs 20 cr (up 30 pc !!!)
Domestic formulation sales grew 16 pc (now at 66 pc of business). New product contribution now at 29 pc ( ie products launched after 2019 ). Volume growth @ 6 pc. Doing well wrt growth in Rheumatology , Monoclonal Anti-Bodies business
Sales force productivity crosses Rs 5 lakh mark
Intl Formulation sales grew 15 pc (now at 19 pc of sales)
APIs grew 7 pc (now at 15 pc of sales )
Debt/Equity - Zero
Management guidance -
Margins to slowly keep increasing as the business scales up
Chronic products sales is slowly increasing. Likely to continue
Have identified 45 new products ( completely new + line extensions ) for domestic and international formulation business - to be launched in next couple of yrs
Most of plant modernisation capex to be over by end of FY 24 ( spending 100 cr on the same )
Disc: holding, biased, not SEBI registered
Subscribe To Our Free Newsletter |